Search tips
Search criteria 


Logo of homepage
Genes and Immunity
Genes Immun. 2010 December; 11(8): 665–670.
Published online 2010 October 7. doi:  10.1038/gene.2010.41
PMCID: PMC3001954

PTX3 genetic variations affect the risk of Pseudomonas aeruginosa airway colonization in cystic fibrosis patients


Cystic fibrosis (CF) is a common life-threatening autosomal recessive disorder in the Caucasian population, and the gene responsible is the CF transmembrane conductance regulator (CFTR). Patients with CF have repeated bacterial infection of the airways caused by Pseudomonas aeruginosa (PA), which is one of the predominant pathogen, and endobronchial chronic infection represents a major cause of morbidity and mortality. Pentraxin 3 (PTX3) is a gene that encodes the antimicrobial protein, PTX3, which is believed to have an important role in innate immunity of lung. To address the role of PTX3 in the risk of PA lung colonization, we investigated five single nucleotide polymorphisms of PTX3 gene in 172 Caucasian CF patients who were homozygous for the F508del mutation. We observed that PTX3 haplotype frequencies were significantly different between patients with PA colonization, as compared with noncolonized patients. Moreover, a protective effect was found in association with a specific haplotype (odds ratio 0.524). Our data suggest that variations within PTX3 affect lung colonization of Pseudomonas in patients with CF.

Keywords: cystic fibrosis, Pseudomonas aeruginosa, modifier genes, gene polymorphism, pentraxin 3, innate immunity

Cystic fibrosis (CF) is a complex condition affecting a number of organs, including the exocrine pancreas, intestine, sweat glands and lung; the effects of the latter are the major cause of disease morbidity and early mortality. Identification of the CF transmembrane conductance regulator (CFTR) gene in 19891 was followed by discovery of hundreds of mutant CFTR alleles (CFTR database on and by attempts at genotype–phenotype correlations.2 The associations between CFTR genotype and exocrine pancreatic and sweat gland phenotypes were soon found to be greater than the association between CFTR genotype and the pulmonary phenotype.2, 3 The clinical outcome of pulmonary disease in CF patients is extremely variable, even among patients with the same CFTR genotype. This variability could arise from some combination of environmental and modifier gene effects.

Patients with CF have repeated bacterial infection of the airways since the first month of life; Pseudomonas aeruginosa (PA) is one of the predominant pathogen and can lead to endobronchial chronic infection. Pathogen recognition is one of the key mechanisms of innate immunity, and is mediated by transmembrane, cytosolic and secreted soluble pattern recognition receptors.4 Pentraxin 3 (PTX3) is a prototypic long pentraxin that has a nonredundant role in the antimicrobial response against multiple pathogens including PA.5

Pentraxins are a superfamily of conserved proteins that are characterized by a cyclic multimeric structure, usually pentameric structure.6, 7, 8, 9 The classical short pentraxins, C-reactive protein and serum amyloid P component, are acute-phase proteins produced in the liver in response to inflammatory mediators. PTX3 shares similarities with the classical short pentraxins; however, it has an unrelated long amino-terminal domain coupled to the carboxy-terminal pentraxin domain, and differs in gene organization, cellular source and ligands recognition.9 PTX3 is rapidly produced and released by several cell types, in particular by mononuclear phagocytes, dendritic cells, fibroblasts and endothelial cells,9, 10, 11 in response to primary inflammatory signals. PTX3 binds the complement component C1q, the extracellular matrix component tumor necrosis factor-α-induced protein 6 and selected microorganisms such as PA with high affinity.

Studies in PTX3-deficient mice suggest that PTX3 has a role in innate resistance to bacterial infection, such as PA. Lung infection of PTX3-deficient mice by PA showed an increase in mortality and lung colonization.12 Moreover, a role for PTX3 gene, as potential modifier, has been hypothesized for susceptibility to pulmonary tuberculosis in an African population.13

The human PTX3 gene, localized on human chromosome 3 band q25, is organized in three exons separated by two introns and covers ~7 Kb (Figure 1). We analyzed five single nucleotide polymorphisms (SNPs) of PTX3, (without including any other gene in the analysis), which included three intronic (rs2305619, rs1840680 and rs3845978) and two exonic (synonymous mutation in rs35948036, nonsynonymous mutation in rs3816527) (Table 1) SNPs. The allelic frequency in Caucasian population for the SNPs rs2305619, rs3594S036 and rs3845978 was reported in NCBI database, whereas SNPs rs1840680 and rs3816527 were validated by our group in a control population.

Figure 1
PTX3 gene maps with position of SNPs.
Table 1
Single nucleotide polymorphism (SNP) information

In this work, we analyzed the role of five SNPs of PTX3 in 127 CF Caucasian patients homozygous for F508del (age [gt-or-equal, slanted]11 years), for the development of chronic PA colonization.

The genotype-allele distribution for PTX3 polymorphisms followed the Hardy–Weinberg equilibrium, and allelic frequencies were comparable among patients and controls (Table 2a). Allelic distribution of five PTX3 polymorphisms was analyzed in 75 CF patients with chronic PA colonization (PA patients), as compared with 52 subjects without evidence of persistent PA growth in bronchial secretions (non-PA patients) (Table 2b). Analysis of SNPs frequencies in CF patients has shown that distribution of two intronic SNPs (rs1840680 and rs2305619) and one exonic SNP (rs3816527) were different between group of patients with or without PA chronic colonization. In particular, statistical analysis has shown that the intronic rs2305619 and rs1840680 alleles and the exonic allele rs3816527 are statistically associated (χ2-test: P=0.012, P=0.016 and P=0.038, respectively) with PA colonization. However, after permutation test (1000 permutations), PA colonization was significantly associated only with rs2305619.

Table 2a
Frequency distributions of PTX3 gene single nucleotide polymorphisms (SNPs) in patients and controls
Table 2b
Frequency distributions of PTX3 gene single nucleotide polymorphisms (SNPs) in patients with (PA) and without (non-PA) PA colonization

Analysis of distribution of SNP genotypes among patients (Table 3) has revealed a recessive model for exonic SNPs (rs35948036 and rs3816527) and a dominant model for intronic SNPs (rs2305619 and rs1840680). Although we could not define the phenotype model for the intronic SNP, rs3845978, because the genotype T/T was not observed in our patients group, calculation of odds ratio (OR) values on the basis of a dominant model for SNPs rs2305619 (OR=2.69; 95% confidence interval (CI): 1.14–6.35) and rs1840680 (OR=2.54; 95% CI: 1.07–6.00) have shown a positive association with PA colonization, suggesting that these SNPs might increase the risk of bacterial colonization in CF patients. In contrast, calculation of OR on the basis of a recessive model for exonic SNPs rs35948036 (OR=0.72, 95% CI=0.06–8.11) and rs3816527 (OR=0.54, 95% CI=0.25–1.14) suggests that these genotypes might be protective for PA colonization.

Table 3
Genotype distribution of SNPs in PA and non-PA patients

Next, we have compared the haplotype frequencies between PA patients and non-PA patients (Table 4). We observed that the two haplotypes, T-A-G-A-G and T-A-C-A-C (SNPs position: rs35948036-rs2305619-rs3816527-rs1840680-rs3845678) are significantly associated (T-G-A-G-C, P=0.016; T-A-C-A-C, P=0.037). In particular, we observed that T-G-A-G-C haplotype was present in 54.6% of CF patients not colonized by PA, as compared with 39.3% of PA-colonized patients. In contrast, the haplotype T-A-C-A-C was present at higher frequency in PA patients (50.0%), as compared with noncolonized patients (36.8%). After permutation test, no haplotype association preserved a significant P-value; therefore, haplotype analysis was restricted to a sub-group of SNPs. Firstly, we have analyzed the haplotype that included the three SNPs associated with PA colonization (intronic SNPs rs2305619 and rs1840680, exonic SNP rs3816527). Analysis of the G-A-G haplotype has shown that this haplotype (P-value=0.012, χ2=6.281) was present in 58.7% of non-PA patients (42.7% of PA patients), whereas the A-C-A haplotype (P-value=0.038, χ2=4.297) was more common in PA patients (50.7%), as compared with non-PA colonized patients (37.5%). After permutation test, G-A-G haplotype preserved a significant P-value (0.030). Secondly, we have added the other exonic SNP rs35948036 to the analysis of these three SNPs (rs2305619, rs1840680 and rs3816527). Even after this analysis, we observed a similar trend. The T-G-A-G haplotype (P-value=0.007) was more common in noncolonized patients (57.7%) than in PA-colonized patients (40.7%), whereas, the T-A-C-A haplotype (P-value=0.038) was present in 50.7% of PA patients, as compared with 37.5% of non-PA patients. After permutation test, the T-G-A-G haplotype preserved a significant P-value (0.029). Haplotype trend regression analyses were followed by linkage disequilibrium analysis within PTX3 gene, using the HaploView software (Broad Institute, Cambridge, MA, USA; Figure 2).

Figure 2
HaploView figures. Linkage disequilibrium (LD) plots characterizing haplotype blocks in PTX3 gene. In the first column are LD plots for PA colonization patients and in the second column are LD plots for patients without PA colonization. D′ values ...
Table 4
PTX3 haplotype trend regression results for extended haplotypes

We have observed a significant association of one PTX3 polymorphism with chronic PA lung colonization in CF patients with homozygous F508del CFTR mutation. A haplotype association in PTX3 gene was also identified in these patients, suggesting that PTX3 protein is involved in preventing lung colonization by this opportunistic pathogen in CF patients. A previous study by Olesen et al.13 reported an association of the same PTX3 haplotype with pulmonary tuberculosis risk in West Africa, in particular, a lower frequency of the rs2305619, rs3816527 and rs1840680 SNPs was observed in patients with pulmonary tuberculosis, as compared with control population. The results of our study, which will need further confirmations, suggest that the same haplotype (rs2305619, rs3816527 and rs1840680) was protective for risk of lung colonization by PA in CF patients. These observations sustain the hypothesis that the long pentraxin PTX3 has a nonredundant function in microbial recognition and subsequent clearance of microbial pathogens of the lower respiratory tract, including PA and Mycobacterium tuberculosis. PTX3 is stored in specific granules of neutrophils and in other intracellular storage compartments of dendritic cells and monocytes, ready to be released in response to inflammatory and/or microbial stimuli.14 Once PTX3 is released in the extracellular space, it can bind specific pathogens such as fungi, bacteria and viruses, promoting their phagocytosis and removal from tissues.15, 16

Although the clinical heterogeneity of lung disease in CF patients with the same CFTR mutation is related to multiple genetic and environmental factors, it is currently well established that chronic lung colonization by PA represents an important determinant for the progression of lung damage in CF patients. Because we have observed that a specific haplotype of PTX3 gene is associated with chronic PA colonization of the lung in CF patients, it is likely that the genetic variants of PTX3 might ultimately influence the severity of CF lung disease. However, we failed to detect in our cohort of CF patients any correlation of respiratory parameters, including FEV1, with any PTX3 gene polymorphisms, suggesting that the contribution of these genetic variants to lung disease progression needs to be investigated in a larger sample of CF patients. This observation is in agreement with a previous report by Tesse et al.17, showing that specific gene polymorphisms of the DEFB1 gene encoding for the antimicrobial peptide β-defensin-1 are associated with chronic PA colonization, but do not correlate with abnormal lung function parameters. Other investigators have sought to associate genetic variations in genes encoding for cytokines with a key role in inflammatory response with lung disease progression in CF.18 However, no genetic variants of the genes encoding for cytokines such as tumor necrosis factor-α, lymphotoxin-α, interleukin (IL) 1-β, IL-1 receptor antagonist, IL-6, IL-8 and IL-10 were linked with impairment of lung function.18 Although variants in the gene encoding for the transforming growth factor-β 1 were associated with lung function decline in a large cohort of CF patients, it was not confirmed in a smaller cohort.19

Analysis of genetic variants in the mannose-binding lectin (MBL) gene in children and adults with CF has revealed that adult patients who were homozygous for the rare variant of MBL had significantly reduced survival, as compared with patients carrying the common genotypes.20 However, this association of MBL variants with lung functions was not reproducible in the pediatric cohort, unless after correction for confounding factors.21 Similarly, the use of proportional hazards regression models has shown that in patients carrying specific IL-8 variants, PA chronic colonization occurs at an older age of 18 years, suggesting a protective effect of this gene against lung disease progression.

It is interesting that all the studies seeking to establish a correlation between lung disease progression and/or PA chronic colonization with genetic variants of modifier genes have revealed a key role for genes encoding antimicrobial proteins such as DEFB, MBL and PTX3, or for IL-8, which encodes for the neutrophil chemotactic protein IL-8. Because all these antimicrobial proteins and the chemotactic factor IL-8 are released in large amounts during lung infections, it is conceivable to hypothesize that their genetic variants might confer susceptibility/resistance against common opportunistic pathogens that are isolated from CF patients with respiratory infection.


We thank Dr Chiara Magri for critically evaluating the paper. This work was supported by grants from Telethon GGP05095, Fondazione Cariplo NOBEL Grant, EU grant FP7 HLH-cure (project no. 201461), e-rare EU grant, Rare Diseases-ISS project, PRIN 2007 no. 2007ACZMMZ_005, Associazione Davide Rodella Onlus.


The authors declare no conflict of interest.


  • Kerem B, Rommens JM, Buchanan JA, Markiewicz D, Cox TK, Chakravarti A, et al. Identification of the cystic fibrosis gene: genetic analysis. Science. 1989;245:1073–1080. [PubMed]
  • Kerem E, Corey M, Kerem BS, Rommens J, Markiewicz D, Levison H, et al. The relation between genotype and phenotype in cystic fibrosis—analysis of the most common mutation (delta F508) N Engl J Med. 1990;323:1517–1522. [PubMed]
  • Kristidis P, Bozon D, Corey M, Markiewicz D, Rommens J, Tsui LC, et al. Genetic determination of exocrine pancreatic function in cystic fibrosis. Am J Hum Genet. 1992;50:1178–1184. [PubMed]
  • Medzhitov R. Toll-like receptors and innate immunity. Nat Rev Immunol. 2001;1:135–145. [PubMed]
  • Diniz SN, Nomizo R, Cisalpino PS, Teixeira MM, Brown GD, Mantovani A, et al. PTX3 function as an opsonin for the dectin-1-dependent internalization of zymosan by macrophages. J Leukoc Biol. 2004;75:649–656. [PubMed]
  • Pepys MB, Baltz ML. Acute phase proteins with special reference to C-reactive protein and related proteins (pentaxins) and serum amyloid A protein. Adv Immunol. 1983;34:141–212. [PubMed]
  • Suffredini AF, Fantuzzi G, Badolato R, Oppenheim JJ, O'Grady NP. New insights into the biology of the acute phase response. J Clin Immunol. 1999;19:203–214. [PubMed]
  • Baumann H, Gauldie J. The acute phase response. Immunol Today. 1994;15:74–80. [PubMed]
  • Garlanda C, Bottazzi B, Bastone A, Mantovani A. Pentraxins at the crossroads between innate immunity, inflammation, matrix deposition, and female fertility. Annu Rev Immunol. 2005;23:337–366. [PubMed]
  • Doni A, Peri G, Chieppa M, Allavena P, Pasqualini F, Vago L, et al. Production of the soluble pattern recognition receptor PTX3 by myeloid, but not plasmacytoid, dendritic cells. Eur J Immunol. 2003;33:2886–2893. [PubMed]
  • Nauta AJ, de Haij S, Bottazzi B, Mantovani A, Borrias MC, Aten J, et al. Human renal epithelial cells produce the long pentraxin PTX3. Kidney Int. 2005;67:543–553. [PubMed]
  • Garlanda C, Hirsch E, Bozza S, Salustri A, De Acetis M, Nota R, et al. Non-redundant role of the long pentraxin PTX3 in anti-fungal innate immune response. Nature. 2002;420:182–186. [PubMed]
  • Olesen R, Wejse C, Velez DR, Bisseye C, Sodemann M, Aaby P, et al. DC-SIGN (CD209), pentraxin 3 and vitamin D receptor gene variants associate with pulmonary tuberculosis risk in West Africans. Genes Immun. 2007;8:456–467. [PubMed]
  • Jaillon S, Peri G, Delneste Y, Fremaux I, Doni A, Moalli F, et al. The humoral pattern recognition receptor PTX3 is stored in neutrophil granules and localizes in extracellular traps. J Exp Med. 2007;204:793–804. [PMC free article] [PubMed]
  • Garlanda C, Hirsch E, Bozza S, Salustri A, De Acetis M, Nota R, et al. Non-redundant role of the long pentraxin PTX3 in anti-fungal innate immune response. Nature. 2002;420:182–186. [PubMed]
  • Jeannin P, Bottazzi B, Sironi M, Doni A, Rusnati M, Presta M, et al. Complexity and complementarity of outer membrane protein A recognition by cellular and humoral innate immunity receptors. Immunity. 2005;22:551–560. [PubMed]
  • Tesse R, Cardinale F, Santostasi T, Polizzi A, Manca A, Mappa L, et al. Association of beta-defensin-1 gene polymorphisms with Pseudomonas aeruginosa airway colonization in cystic fibrosis. Genes Immun. 2008;9:57–60. [PubMed]
  • Corvol H, Boelle PY, Brouard J, Knauer N, Chadelat K, Henrion-Caude A, et al. Genetic variations in inflammatory mediators influence lung disease progression in cystic fibrosis. Pediatr Pulmonol. 2008;43:1224–1232. [PubMed]
  • Brazova J, Sismova K, Vavrova V, Bartosova J, Macek M, Jr, Lauschman H, et al. Polymorphisms of TGF-beta 1 in cystic fibrosis patients. Clin Immunol. 2006;121:350–357. [PubMed]
  • Garred P, Pressler T, Madsen HO, Frederiksen B, Svejgaard A, Hoiby N, et al. Association of mannose-binding lectin gene heterogeneity with severity of lung disease and survival in cystic fibrosis. J Clin Invest. 1999;104:431–437. [PMC free article] [PubMed]
  • McDougal KE, Green DM, Vanscoy LL, Fallin MD, Grow M, Cheng S, et al. Use of a modeling framework to evaluate the effect of a modifier gene (MBL2) on variation in cystic fibrosis. Eur J Hum Genet. 2010;18:680–684. [PMC free article] [PubMed]
  • Gibson LE, Cooke RE. A test for concentration of electrolytes in sweat in cystic fibrosis of the pancreas utilizing pilocarpine by iontophoresis. Pediatrics. 1959;23:545–549. [PubMed]

Articles from NPG Open Access are provided here courtesy of Nature Publishing Group